IGM Biosciences
IGMS
IGMS was delisted on the 13th of August, 2025.
109 hedge funds and large institutions have $1.38B invested in IGM Biosciences in 2021 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 40 increasing their positions, 34 reducing their positions, and 14 closing their positions.
18% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 34
14% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 14
3.22% more ownership
Funds ownership: 67.39% → 70.61% (+3.2%)
2% more funds holding
Funds holding: 107 → 109 (+2)
9% less capital invested
Capital invested by funds: $1.52B → $1.38B (-$135M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
74% less call options, than puts
Call options by funds: $7.08M | Put options by funds: $27.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$48.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$42.6M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$19.4M |
| 4 |
State Street
Boston,
Massachusetts
|
+$13M |
| 5 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$11.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$21.2M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$13.2M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$9.99M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$9.49M |
| 5 |
AG
Artal Group
Luxembourg
|
-$6.83M |
IGMS Hedge Fund Activity: Q1 2021 in Review
109 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q1 2021, worth a combined $1.38B — down 8.9% from $1.52B a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new IGMS positions and 14 closed out — a net gain of 2 holders — while 40 added to existing stakes and 34 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $48.7M. The largest seller was Janus Henderson Group, cutting an estimated $21.2M.
- 109 institutional investors held IGM Biosciences (IGMS) as of Q1 2021, up from 107 in Q4 2020.
- Funds reported $1.38B of IGM Biosciences stock for Q1 2021, down 8.9% quarter-over-quarter.
- 16 funds opened new IGM Biosciences positions in Q1 2021 and 14 closed out, a net change of +2 holders.
- The largest IGM Biosciences buyer in Q1 2021 was Goldman Sachs, an estimated $48.7M added.
- The largest IGM Biosciences seller in Q1 2021 was Janus Henderson Group, an estimated $21.2M sold.
Based on aggregated 13F filings for Q1 2021.